Trinity Biotech (TRIB) Non-Current Assets (2009 - 2025)

Trinity Biotech has disclosed Non-Current Assets across 17 years of filings, most recently posting $69.3 million for Q4 2025.

• Non-Current Assets for Q4 2025 came in at $69.3 million, up 11.42% year-over-year; the trailing twelve-month figure through Dec 2025 was $69.3 million (up 11.42% YoY), and the FY2025 annual result was $69.3 million, up 11.42% from the prior year.
• Non-Current Assets came in at $69.3 million for Q4 2025 at Trinity Biotech, up from $66.6 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $69.3 million in Q4 2025 to a low of $19.1 million in Q2 2023.
• The 5-year median for Non-Current Assets is $47.0 million (2021), against an average of $44.9 million.
• Across the five-year window, Non-Current Assets plunged 61.78% in 2023 and jumped 204.82% in 2024, its largest moves.
• Trinity Biotech's Non-Current Assets stood at $46.2 million in 2021, then declined by 1.67% to $45.4 million in 2022, then plunged by 55.11% to $20.4 million in 2023, then surged by 204.82% to $62.2 million in 2024, then gained by 11.42% to $69.3 million in 2025.
• The last three Non-Current Assets figures came in at $69.3 million (Q4 2025), $66.6 million (Q2 2025), and $62.2 million (Q4 2024), per Business Quant data.